β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides

Takanobu Yoshimoto, Mitsuhide Naruse, Kaoru Ire, Akiyo Tanabe, Toshirou Seki, Masami Tanaka, Toshihiro Imaki, Kiyoko Naruse, Takamura Muraki, Yuzuru Matsuda, Hiroshi Demura

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

β-Adrenoceptor antagonists are known to increase plasma atrial natriuretic peptide (ANP) levels despite their hypotensive action. The aim of the present study was to examine the role of the ANP system in the antihypertensive effects of a β-adrenoceptor antagonist. We investigated the effects of propranolol (75 mg kg-1 day-1, p.o., 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats. Plasma ANP levels were significantly higher in the propranolol group than in the control group. Both receptor densities and mRNA levels of ANP(C) receptor were significantly decreased in the lung as the major site of ANP clearance from the circulation. In contrast, both central venous pressure and ANP mRNA levels in the heart were not significantly different between the two groups. Under both basal and ANP-stimulated conditions, the cGMP content in the aorta was significantly greater in the propranolol group than in the control group, whereas the basal and stimulated cGMP content of the kidney was similar in the two groups. Inhibition of endogenous ANP action by a specific ANP receptor antagonist, HS-142-1, produced a greater increase of blood pressure in the propranolol group than in the control group. These results suggest potentiation of natriuretic peptide activity as a new antihypertensive mechanism of the β-adrenoceptor antagonist propranolol.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalEuropean journal of pharmacology
Volume351
Issue number1
DOIs
Publication statusPublished - 1998 Jun 12
Externally publishedYes

Fingerprint

Natriuretic Peptides
Atrial Natriuretic Factor
Propranolol
Adrenergic Receptors
Atrial Natriuretic Factor Receptors
Control Groups
Antihypertensive Agents
Messenger RNA
Central Venous Pressure
Inbred SHR Rats
Aorta
Stroke
Blood Pressure
Kidney
Lung

Keywords

  • β-Adrenoceptor antagonist
  • ANP receptor
  • Hypertension
  • Natriuretic peptide

ASJC Scopus subject areas

  • Pharmacology

Cite this

β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides. / Yoshimoto, Takanobu; Naruse, Mitsuhide; Ire, Kaoru; Tanabe, Akiyo; Seki, Toshirou; Tanaka, Masami; Imaki, Toshihiro; Naruse, Kiyoko; Muraki, Takamura; Matsuda, Yuzuru; Demura, Hiroshi.

In: European journal of pharmacology, Vol. 351, No. 1, 12.06.1998, p. 61-66.

Research output: Contribution to journalArticle

Yoshimoto, T, Naruse, M, Ire, K, Tanabe, A, Seki, T, Tanaka, M, Imaki, T, Naruse, K, Muraki, T, Matsuda, Y & Demura, H 1998, 'β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides', European journal of pharmacology, vol. 351, no. 1, pp. 61-66. https://doi.org/10.1016/S0014-2999(98)00291-X
Yoshimoto, Takanobu ; Naruse, Mitsuhide ; Ire, Kaoru ; Tanabe, Akiyo ; Seki, Toshirou ; Tanaka, Masami ; Imaki, Toshihiro ; Naruse, Kiyoko ; Muraki, Takamura ; Matsuda, Yuzuru ; Demura, Hiroshi. / β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides. In: European journal of pharmacology. 1998 ; Vol. 351, No. 1. pp. 61-66.
@article{b5024d8f62424374b2376a886081a815,
title = "β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides",
abstract = "β-Adrenoceptor antagonists are known to increase plasma atrial natriuretic peptide (ANP) levels despite their hypotensive action. The aim of the present study was to examine the role of the ANP system in the antihypertensive effects of a β-adrenoceptor antagonist. We investigated the effects of propranolol (75 mg kg-1 day-1, p.o., 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats. Plasma ANP levels were significantly higher in the propranolol group than in the control group. Both receptor densities and mRNA levels of ANP(C) receptor were significantly decreased in the lung as the major site of ANP clearance from the circulation. In contrast, both central venous pressure and ANP mRNA levels in the heart were not significantly different between the two groups. Under both basal and ANP-stimulated conditions, the cGMP content in the aorta was significantly greater in the propranolol group than in the control group, whereas the basal and stimulated cGMP content of the kidney was similar in the two groups. Inhibition of endogenous ANP action by a specific ANP receptor antagonist, HS-142-1, produced a greater increase of blood pressure in the propranolol group than in the control group. These results suggest potentiation of natriuretic peptide activity as a new antihypertensive mechanism of the β-adrenoceptor antagonist propranolol.",
keywords = "β-Adrenoceptor antagonist, ANP receptor, Hypertension, Natriuretic peptide",
author = "Takanobu Yoshimoto and Mitsuhide Naruse and Kaoru Ire and Akiyo Tanabe and Toshirou Seki and Masami Tanaka and Toshihiro Imaki and Kiyoko Naruse and Takamura Muraki and Yuzuru Matsuda and Hiroshi Demura",
year = "1998",
month = "6",
day = "12",
doi = "10.1016/S0014-2999(98)00291-X",
language = "English",
volume = "351",
pages = "61--66",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - β-Adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides

AU - Yoshimoto, Takanobu

AU - Naruse, Mitsuhide

AU - Ire, Kaoru

AU - Tanabe, Akiyo

AU - Seki, Toshirou

AU - Tanaka, Masami

AU - Imaki, Toshihiro

AU - Naruse, Kiyoko

AU - Muraki, Takamura

AU - Matsuda, Yuzuru

AU - Demura, Hiroshi

PY - 1998/6/12

Y1 - 1998/6/12

N2 - β-Adrenoceptor antagonists are known to increase plasma atrial natriuretic peptide (ANP) levels despite their hypotensive action. The aim of the present study was to examine the role of the ANP system in the antihypertensive effects of a β-adrenoceptor antagonist. We investigated the effects of propranolol (75 mg kg-1 day-1, p.o., 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats. Plasma ANP levels were significantly higher in the propranolol group than in the control group. Both receptor densities and mRNA levels of ANP(C) receptor were significantly decreased in the lung as the major site of ANP clearance from the circulation. In contrast, both central venous pressure and ANP mRNA levels in the heart were not significantly different between the two groups. Under both basal and ANP-stimulated conditions, the cGMP content in the aorta was significantly greater in the propranolol group than in the control group, whereas the basal and stimulated cGMP content of the kidney was similar in the two groups. Inhibition of endogenous ANP action by a specific ANP receptor antagonist, HS-142-1, produced a greater increase of blood pressure in the propranolol group than in the control group. These results suggest potentiation of natriuretic peptide activity as a new antihypertensive mechanism of the β-adrenoceptor antagonist propranolol.

AB - β-Adrenoceptor antagonists are known to increase plasma atrial natriuretic peptide (ANP) levels despite their hypotensive action. The aim of the present study was to examine the role of the ANP system in the antihypertensive effects of a β-adrenoceptor antagonist. We investigated the effects of propranolol (75 mg kg-1 day-1, p.o., 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats. Plasma ANP levels were significantly higher in the propranolol group than in the control group. Both receptor densities and mRNA levels of ANP(C) receptor were significantly decreased in the lung as the major site of ANP clearance from the circulation. In contrast, both central venous pressure and ANP mRNA levels in the heart were not significantly different between the two groups. Under both basal and ANP-stimulated conditions, the cGMP content in the aorta was significantly greater in the propranolol group than in the control group, whereas the basal and stimulated cGMP content of the kidney was similar in the two groups. Inhibition of endogenous ANP action by a specific ANP receptor antagonist, HS-142-1, produced a greater increase of blood pressure in the propranolol group than in the control group. These results suggest potentiation of natriuretic peptide activity as a new antihypertensive mechanism of the β-adrenoceptor antagonist propranolol.

KW - β-Adrenoceptor antagonist

KW - ANP receptor

KW - Hypertension

KW - Natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=0032511130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032511130&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(98)00291-X

DO - 10.1016/S0014-2999(98)00291-X

M3 - Article

C2 - 9698206

AN - SCOPUS:0032511130

VL - 351

SP - 61

EP - 66

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -